Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical ...

Leiden, the Netherlands, August 4, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor ...

Paris, France (4 August 2025) – EssilorLuxottica announces today the acquisition of Automation & Robotics (A&R), a renowned player in the design and manufacture of automated systems for optical lens ...

AB Science S.A. (la “ Société ” ou “ AB Science ”, Euronext – FR0010557264 – AB) annonce aujourd'hui le succès d'une augmentation de capital d'un montant brut total de 2,55 millions d’euros souscrite ...

VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial ...

Tevogen has rapidly evolved from a biotechnology innovator into a dynamic enterprise expanding into artificial intelligence through Tevogen.AI. Our mission remains steadfast: delivering clinically ...

We encourage physicians in the northeastern United States to seize this opportunity to offer the SVDx test to their patients. By identifying vascular risks earlier, healthcare providers can implement ...

The inducement stock options have an exercise price of $16.37 per share, the closing price of ImageneBio’s common stock on July 28, 2025, are non-qualified stock options, have a ten-year term and vest ...

Funds will support advancement of Tevogen.AI, the Company’s artificial intelligence–driven drug discovery initiative. The $1 million is part of up to $10 million in previously announced non‑dilutive ...

The shares of common stock were offered by Prime Medicine pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission ...

In the Portal study (n = 352), people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort; n = 220), while those originally treated with ...

(“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that in the Hospital Inpatient Prospective Payment Systems Final Rule (IPPS) for ...